Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - ALDER BIOPHARMACEUTICALS INC | aldr-ex991_6.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 26, 2016
Alder BioPharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
001-36431 |
|
90-0134860 |
|
(State or other jurisdiction |
|
(Commission |
|
(IRS Employer |
|
11804 North Creek Parkway South Bothell, WA |
|
98011 |
|
(Address of principal executive offices) |
|
(Zip Code) |
(425) 205-2900
Registrant’s telephone number, including area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02 Results of Operations and Financial Condition.
On July 26, 2016, Alder BioPharmaceuticals, Inc. (“Alder”) issued a press release announcing financial results for the quarter ended June 30, 2016. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated herein by reference.
The information in this report, including the exhibit hereto, is being furnished and shall not be deemed ‘‘filed’’ for purposes of Section 18 of the Securities Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Alder, whether made before, on or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No. |
|
Description |
|
99.1 |
|
Press Release of Alder BioPharmaceuticals, Inc. issued July 26, 2016 |
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
Alder BioPharmaceuticals, Inc. |
|
|
|
|
|
|
|
Dated: July 26, 2016 |
|
|
|
|
|
|
By: |
/s/ Randall C. Schatzman |
|
|
|
|
Randall C. Schatzman, Ph.D. |
|
|
|
|
President and Chief Executive Officer |
|
Exhibit No. |
|
Description |
|
99.1 |
|
Press Release of Alder BioPharmaceuticals, Inc. issued July 26, 2016 |